Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Fluvastatin associated with beneficial effects in CAD patients with low HDL cholesterol levels

June 9, 1999

Policosanol in patients with hyperlipidemia and coronary risk factors

June 8, 1999

Approval recommended for nateglinide in Japan

June 7, 1999

Fujisawa studies inhibitors of vacuolar H+-ATPase as bone resorption inhibitors

June 7, 1999

Watson reacquires North American marketing rights to Androderm

June 7, 1999

Alteon completes phase I human trials of ALT-711

June 7, 1999

Benzenes with hypoglycemic and hypolipidemic effects in the Ono pipeline

June 4, 1999

Hematopoietic agents in development at Toray

June 4, 1999

LY-333531 reduces leukocyte accumulation in retinal microcirculation of diabetic rats

June 4, 1999

Preclinical study indicates potential of OGT-918 in treating complicated metabolic disorders

June 3, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...